Endocrinology Today—March 31, 2026

This week’s Endocrinology update highlights regulatory progress, access expansion, digital care initiatives, device innovation, and strategic partnerships across metabolic and endocrine disorders.

In Today’s Newsletter

Dive deeper

🏃 BetterMe launches diabetes-friendly workouts [1] [UK • 24 Mar 2026]

https://www.prnewswire.com/news-releases/betterme-launches-diabetes-friendly-workouts-to-support-people-living-with-the-condition-in-collaboration-with-diabetes-uk-302723184.html
Context: Program developed with Diabetes UK; includes 28 beginner sessions combining strength, cardio, and recovery.
Key point: BetterMe (digital health platform) introduced a diabetes-specific workout program to support glucose management and confidence in exercise.
Implication: Could streamline initiation and adherence via remote prescribing and logistics.

🧬 Continuity Biosciences x Breakthrough T1D advance NICHE® platform [2] [US • 24 Mar 2026]

https://www.prnewswire.com/news-releases/continuity-biosciences-y-breakthrough-t1d-colaboran-para-impulsar-la-plataforma-de-terapia-celular-niche-302723524.html
Context: Planned Phase 1/2a first-in-human study; implantable system aims to support islet survival and localized immunomodulation.
Key point: Continuity Biosciences (NICHE® platform) and Breakthrough T1D partnered to enable IND submission and early clinical testing in type 1 diabetes.
Implication: Signals pipeline investment and modality expansion.

💉 Novo Nordisk’s Awiqli (insulin icodec) wins FDA approval [6] [US • 27 Mar 2026]

https://www.tradingview.com/news/zacks:36cb7cab4094b:0-novo-nordisk-s-awiqli-gets-fda-approval-for-type-ii-diabetes/
Context: Phase 3a ONWARDS program (~2,680 adults); evaluated vs daily basal insulin; safety consistent with class.
Key point: Novo Nordisk (Awiqli, once-weekly basal insulin) approved to improve glycemic control in adults with type 2 diabetes.
Implication: May influence prescriber choice and payer reviews pending full data.

💊 Hetero launches generic semaglutide in emerging markets [5] [28 Mar 2026]

https://medicarepharmabusiness.com/hetero-debuts-semaglutide-generic-in-emerging-markets/
Context: Rollout across 75+ countries; multi-dose pen formats targeting diabetes and weight loss indications.
Key point: Hetero introduced generic semaglutide brands (GLP-1 receptor agonist) across Asia, Africa, and the Middle East.
Implication: Introduces competition that may affect pricing and formulary access.

🩸 Glucotrack plans U.S. trial for implantable CGM [4] [US • 27 Mar 2026]

https://www.medtechdive.com/news/glucotrack-plans-us-trial-of-implantable-glucose-monitor-this-year/816006/
Context: Device implanted in subclavian vein; prior small feasibility studies showed accuracy and no major safety signals (n small).
Key point: Glucotrack aims to file IDE and initiate a U.S. clinical trial for a long-duration implantable glucose monitor.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.

🤖 Insilico Medicine x Eli Lilly sign $2.75B AI drug deal [7] [30 Mar 2026]

https://www.businessworld.in/article/insilico-medicine-signs-up-to-2-75-bn-ai-drug-discovery-deal-with-eli-lilly-599815
Context: Includes upfront payment and milestones; covers preclinical oral candidates across selected indications.
Key point: Insilico Medicine (AI drug discovery) granted Eli Lilly rights to develop and commercialize candidates, with deal value up to $2.75B.
Implication: Signals pipeline investment and modality expansion.

🧪 Crinetics files Brazil MAA for paltusotine (Palsonify) [8] [Brazil • 26 Mar 2026]

https://bluestudio.estadao.com.br/agencia-de-comunicacao/releases/releases-geral/crinetics-pharmaceuticals-announces-submission-of-marketing-authorization-application-in-brazil-for-palsonify-paltusotine-in-acromegaly/
Context: Supported by 18 trials including Phase 3; endpoints met (details per source).
Key point: Crinetics Pharmaceuticals submitted MAA to ANVISA for paltusotine, an oral SST2 agonist for acromegaly.
Implication: May influence prescriber choice and payer reviews pending full data.

🧬 Henlius denosumab biosimilars approved in Canada [3] [Canada • 24 Mar 2026]

https://www.henlius.com/en/NewsDetails-5818-26.html
Context: Biosimilars to Prolia and Xgeva; approved for all reference product indications.
Key point: Henlius (BILDYOS®, TUZEMTY®) received Health Canada approval for denosumab biosimilars.
Implication: Introduces competition that may affect pricing and formulary access.

Why It Matters

Weekly insulin (Awiqli) may shift adherence dynamics and treatment algorithms in T2D.
Generic semaglutide expansion signals a transition from premium GLP-1 pricing to broader access.
Implantable CGMs and cell therapy platforms reflect a push toward longer-duration, lower-burden interventions.
AI partnerships (Insilico–Lilly) continue to reshape early-stage drug discovery economics.
Digital health programs (BetterMe) highlight scalable, non-pharmacologic intervention models.

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🎬 Watch on YouTube. Subscribe and never miss a video.

🧰 See our full range of services. Discover how we can help you.

📚 View the full Endocrinology archive on our research hub page.

FAQ

What is Awiqli (insulin icodec) and how is it different from existing insulins?

Awiqli (Novo Nordisk) is a once-weekly basal insulin approved for adults with type 2 diabetes. It showed HbA1c reduction vs daily basal insulin in Phase 3 studies, with comparable safety (details per source) [6].

What is the NICHE® platform by Continuity Biosciences?

NICHE® is an implantable cell therapy system designed to support insulin-producing cells with localized immune protection. The collaboration with Breakthrough T1D aims to move it into first-in-human trials (Phase 1/2a planned) [2].

How significant is Hetero’s generic semaglutide launch?

Hetero’s rollout across 75+ countries targets broader access to GLP-1 therapies. As patents expire, generics may reshape pricing and availability in diabetes and obesity care [5].

What makes Glucotrack’s CGM different?

Glucotrack’s device measures glucose directly in the blood via an implantable sensor, rather than interstitial fluid. A U.S. trial is planned pending FDA IDE approval [4].

What does the Insilico–Lilly deal cover?

The agreement grants Eli Lilly rights to develop AI-discovered drug candidates from Insilico, with total potential value up to $2.75B including milestones and royalties [7].

What is paltusotine (Palsonify) used for?

Paltusotine (Crinetics) is an oral SST2 agonist for acromegaly. It has U.S. approval and is under regulatory review in Brazil following MAA submission [8].

Entities / Keywords

BetterMe (digital health), Diabetes UK, Continuity Biosciences (NICHE®), Breakthrough T1D (JDRF), Novo Nordisk (Awiqli, insulin icodec), Hetero (semaglutide generic), Glucotrack (implantable CGM), Insilico Medicine (AI drug discovery), Eli Lilly, Crinetics Pharmaceuticals (paltusotine, Palsonify), Henlius (denosumab biosimilars, BILDYOS®, TUZEMTY®)